Activating mutations of the serine-threonine kinases NRAS (mutNRAS) or BRAF (mutBRAF) are key drivers of tumor growth through constitutive activation of Mitogen-Activated Protein Kinase (MAPK) pathways involving RAF-MEK-ERK and PI3K-AKT-mTOR, respectively [1–3]. The gene discussed is BRAF; the disease is neoplasm.